Roquefort Therapeutics plc (ROQ.L)

4.5500 +0.1500 (+3.41%) At close: 12:25PM BST

Roquefort Therapeutics plc

85 Great Portland Street
First Floor
London W1W 7LT
United Kingdom
44 20 3918 8633
https://www.roquefortinvest.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen Paul West B.Com, CA	Executive Chairman	152.9k	N/A	1972
Mr. Trevor Ajanthan Reginald	CEO & Executive Director	305.8k	N/A	1972
Prof. Martin J. Evans FRS	Group Chief Scientific Officer & Executive Director	100k	N/A	1941
Dr. Emma Morris	Head of Pre-Clinical Research	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

Corporate governance

Roquefort Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.